Last reviewed · How we verify
TT-4
At a glance
| Generic name | TT-4 |
|---|---|
| Sponsor | Tarus Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (PHASE2)
- Euthyroid Sick Syndrome in Obesity Hypoventilation Syndrome
- TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors (PHASE1, PHASE2)
- TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors (PHASE1, PHASE2)
- Relationship Between Ectopic Pregnancy and Thyroid Disorders
- Thyroid Function in Critically Ill Patients With Acute Kidney Injury
- Thyroid Hormones in Critically Ill Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TT-4 CI brief — competitive landscape report
- TT-4 updates RSS · CI watch RSS
- Tarus Therapeutics, Inc. portfolio CI